Teva Edges Closer To Growth, But With A Big Overhang
Executive Summary
Teva's turnaround is progressing, but the company forecast largely flat revenues and earnings in 2020. A threat to the improved stability is how an opioid litigation settlement might unfold.
You may also be interested in...
Teva’s Complex Generic Ambitions Number Nearly A Dozen In 2021
Israeli giant Teva is hoping to follow the recent big-ticket launches of generic Truvada/Atripla and NuvaRing with multiple complex generics launches in the US this year. Management discussed individual product opportunities as Teva disclosed full-year financial earnings.
Teva's Slow Recovery Proceeds With Flat Revenue Forecast In 2021
The company's specialty franchises are on track for solid growth but the North American generics outlook remains lackluster.
J.P. Morgan Day 3: Preparing For The Future, Whatever That Holds
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Teva promises growth is coming; Relay joins Roche in the KRAS race; UCB embraces the digital age; Agios and Ionis prepare for commercial battles.